Ribociclib and Letrozole in HR Positive, HER2 Negative Disease
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Ribociclib and Letrozole in HR Positive, HER2 Negative Disease

Sponsor: Novartis Pharmaceuticals

Enrolling in our Bronx locations. COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease.